Tobacco Products

Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions

September 2015

October 14, 2016

Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions, Guidance for Industry—Status of Recommendations Related to Label Changes (“SE FAQ Guidance”):

The U.S. District Court for the District of Columbia recently held that “a modification to an existing [tobacco] product’s label does not result in a ‘new tobacco product’” and does not give rise to the substantial equivalence review process. See Philip Morris USA Inc. v. United States Food and Drug Administration, No. 15-cv1590 (APM)(D.D.C. Aug. 16, 2016). The court vacated the SE FAQ Guidance “insofar as it interprets a labeling change as creating a ‘new tobacco product’ under the [Tobacco Control Act]." The court also held that a change in product quantity “creates a new tobacco product that triggers premarket or substantial equivalence review.”

FDA is currently revising the SE FAQ Guidance consistent with the court’s decision and intends to issue the updated version shortly.

Contact FDA

1-877-287-1373
(9am EST-4pm EST)
Tobacco

For General Inquiries:
AskCTP@fda.hhs.gov


Center for Tobacco Products
Food and Drug Administration
10903 New Hampshire Avenue
Document Control Center

Building 71, Room G335
Silver Spring, MD 20993-002


Courier Deliveries

Page Last Updated: 10/14/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English